Cost-effectiveness of a statewide campaign to promote aspirin use for primary prevention of cardiovascular disease

Journal of the American Heart Association

Volumn 4, Issue 12, 2015, Pages

  Michaud, Tzeyu L ^a   Abraham, Jean ^b   Jalal, Hawre ^d   Luepker, Russell V ^b,c   Duval, Sue ^c   Hirsch, Alan T ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Aspirin; Cardiovascular diseases; Cost effectiveness analysis; Epidemiology; Myocardial infarction; Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; AWARENESS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE PLANNING; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH CAMPAIGN; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES; CARDIOVASCULAR DISEASES; ECONOMICS; HEALTH PROMOTION; MARKOV CHAIN; MINNESOTA; PROCEDURES;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH PROMOTION; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MINNESOTA; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS;

EID: 84991523290     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002321     Document Type: Article

References (58)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES. Heart disease and stroke statistics-2011 update. Circulation. 2011;123:e18-e209.
2. Murphy SL, Xu J, Kochanek KD. Deaths: Preliminary Data for 2010. Natl Vital Stat Rep. 2012;60:1.
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S. Heart disease and stroke statistics-2014 update. Circulation. 2014;129:e28-e292.
4. Fryar CD, Chen T, Li X. Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010. NCHS data brief, no 103. Hyattsville, MD: National Center for Health Statistics; 2012.
5. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104:2855-2864.
6. Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C. Community programs for the prevention of cardiovascular disease: a systematic review. Am J Epidemiol. 2010;172:501-516.
7. Ebrahim S, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Libr. 2011;1:CD001561.
8. Hennekens C. Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med. 1989;321:129-135.
9. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
10. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA. 2006;295:306-313.
11. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510-2520.
12. Calonge N, Petitti DB, DeWitt TG, Gordis L, Gregory KD, Harris R, Isham G, LeFevre ML, Loveland-Cherry C, Marion LN. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404.
13. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-391.
14. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010;55:2878-2886.
15. Koh HK. A 2020 vision for healthy people. N Engl J Med. 2010;362:1653-1656.
16. Frieden TR, Berwick DM. The "Million Hearts" initiative-preventing heart attacks and strokes. N Engl J Med. 2011;365:e27.
17. Glasser SP, Hovater MK, Lackland DT, Cushman M, Howard G, Howard VJ. Primary prophylactic aspirin use and incident stroke: reasons for geographic and racial differences in stroke study. J Stroke Cerebrovasc Dis. 2013;22:500-507.
18. Fiscella K, Winters PC, Mendoza M, Noronha GJ, Swanger CM, Bisognano JD, Fortuna RJ. Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease? J Gen Intern Med. 2014;30:155-160.
19. Roth GA, Gillespie CW, Mokdad AA, Shen DD, Fleming DW, Stergachis A, Murray CJL, Mokdad AH. Aspirin use and knowledge in the community: a population-and health facility based survey for measuring local health system performance. BMC Cardiovasc Disord. 2014;14:16.
20. Luepker RV. Minnesota, a good place for your heart: trends in cardiovascular disease. J Cardiovasc Transl Res. 2008;1:301-304.
21. Shanedling S, Jo Mehelich M, Peacock J. The Minnesota Heart Disease and Stroke Prevention Plan 2011-2020. Minn Med. 2012;95:41.
22. Luepker RV, Steffen LM, Jacobs DR, Zhou X, Blackburn H. Trends in blood pressure and hypertension detection, treatment, and control 1980 to 2009 the Minnesota Heart Survey. Circulation. 2012;126:1852-1857.
23. Wang H, Steffen LM, Jacobs DR, Zhou X, Blackburn H, Berger AK, Filion KB, Luepker RV. Trends in cardiovascular risk factor levels in the Minnesota Heart Survey (1980-2002) as compared with the National Health and Nutrition Examination Survey (1976-2002): a partial explanation for Minnesota's low cardiovascular disease mortality? Am J Epidemiol. 2011;173:526-538.
24. Jacobs DR, Luepker RV, Mittelmark MB, Folsom AR, Pirie PL, Mascioli SR, Hannan PJ, Pechacek TF, Bracht NF, Carlaw RW. Community-wide prevention strategies: evaluation design of the Minnesota Heart Health Program. J Chronic Dis. 1986;39:775-788.
25. Luepker RV, Rästam L, Hannan PJ, Murray DM, Gray C, Baker WL, Crow R, Jacobs DR, Pirie PL, Mascioli SR. Community education for cardiovascular disease prevention morbidity and mortality results from the Minnesota Heart Health Program. Am J Epidemiol. 1996;144:351-362.
26. Oldenburg NC, Duval S, Luepker RV, Finnegan JR, LaMarre H, Peterson KA. A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease. Prev Chronic Dis. 2014;11:E83.
27. Luepker RV, Murray DM, Jacobs DR Jr, Mittelmark MB, Bracht N, Carlaw R, Crow R, Elmer P, Finnegan J, Folsom AR. Community education for cardiovascular disease prevention: risk factor changes in the Minnesota Heart Health Program. Am J Public Health. 1994;84:1383-1393.
28. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health. 2012;15:812-820.
29. Ethgen O, Standaert B. Population-versus cohort-based modelling approaches. Pharmacoeconomics. 2012;30:171-181.
30. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117:2875-2883.
31. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007;167:290.
32. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326-336.
33. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258.
34. 2010 U.S. Census. Available at: http://quickfacts.census.gov/qfd/states/27/2728790.html. Accessed February 11, 2014.
35. 2011 Introduction to the HCUP Nationwide Inpatient Sample (NIS). Rockville, MD: Agency for Healthcare Quality and Research (AHRQ); 2013.
36. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-165.
37. Nease RF, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, Pryor D, Sox HC. Variation in patient utilities for outcomes of the management of chronic stable angina: implications for clinical practice guidelines. JAMA. 1995;273:1185-1190.
38. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
39. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 1998;13:824-835.
40. Russell MW, Huse D, Daniel S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81:1110-1115.
41. Buskens E, Nederkoorn PJ, Buijs-van der Woude T, Mali Willem PTM, Kappelle LJ, Eikelboom BC, van der Graaf Y, Myriam Hunink MG. Imaging of carotid arteries in symptomatic patients: cost-effectiveness of diagnostic strategies. Radiology. 2004;233:101-112.
42. Zantek ND, Luepker RV, Duval S, Miller K, Oldenburg N, Hirsch AT. Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement. Clin Appl Thromb Hemost. 2014;20:385-392.
43. 2011 Minnesota Hospital Association. Available at: http://www.mnhospitals. org. Accessed February 27, 2013.
44. Koek H, De Bruin A, Gast A, Gevers E, Kardaun JW, Reitsma JB, Grobbee DE, Bots ML. Incidence of first acute myocardial infarction in the Netherlands. Neth J Med. 2007;65:434-441.
45. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2009;150:405-410.
46. 2011 Minnesota Health Statistics. Available at: http://www.health.state.mn. us/divs/chs/annsum/. Accessed February 11, 2014.
47. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
48. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276:1172-1177.
49. Gold MR. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
50. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
51. 2012 Minnesota medical consumer price index. Available at: http://research.stlouisfed.org/fred2/series/CUUSA211SAM. Accessed February 11, 2014.
52. 2011 Minnesota Vital Statistics. Available at: http://www.health.state.mn. us/divs/chs/trends/. Accessed February 11, 2014.
53. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32:722-732.
54. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of costeffectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290-308.
55. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377-401.
56. Stinnett AA, Mullahy J. Net health benefits a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18:S68-S80.
57. Weinstein MC, Siegel JE, Kamlet MS, Gold MR, Russell LB. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:55.
58. Manson SC, Benedict A, Pan F, Wittrup-Jensen KU, Mark Fendrick A. Potential economic impact of increasing low dose aspirin usage on CVD in the US. Curr Med Res Opin. 2010;26:2365-2373.